| 查看: 322 | 回复: 2 | |||
[交流]
【求助】有没有虫子帮我查一下fasidotril这个药在国外有没有上市？ 已有2人参与
|
|
因为我们单位没啥数据库，所以查不到。 fasidotril 法西多曲 ACE/NEP双向抑制剂 临床试验做到3期，但后来就没下文了，哪位好心的虫子帮个忙呢？帮我把它有没有上市，在哪上市的查一下？ |
回复此楼» 猜你喜欢
药学349专硕求调剂
已经有2人回复
-
《左乙拉西坦注射液制备工艺研究、质量控制和稳定性研究》下载
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有167人回复
-
105500药学求调剂，一志愿山东大学药学，348分
已经有3人回复
nkbeholder
实习版主
- DRDEPI: 1
- 应助: 11 (小学生)
- 金币: 2945.1
- 散金: 4
- 红花: 5
- 帖子: 748
- 在线: 303.7小时
- 虫号: 202353
- 注册: 2006-03-01
- 性别: GG
- 专业: 药物化学
★ ★
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
|
这上面写到2期就中止了。 Originator Company: Bioprojet (France) Parent Company: Bioprojet Licensee: Eli Lilly Highest Phase: Discontinued II Development Status: Discontinued II, France, Congestive heart failure Discontinued II, France, Hypertension Discontinued Preclinical, France, Postmyocardial infarction Introduction: Fasidotril, the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase. It was undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure and hypertension. It was also in preclinical development for postmyocardial infarction. However, development appears to have been discontinued. In October 2001, Bioprojet and Eli Lilly announced a development and commercialisation collaboration. Under the terms of the agreement, Lilly received exclusive worldwide commercialisation rights excluding Japan and certain countries in Europe. Lilly was to continue to develop fasidotril through to registration, and was to manufacture the finished product; Bioprojet was to manufacture the bulk material. |
2楼2010-08-04 14:45:13
mrzouhao
主管区长
- DRDEPI: 1
- 应助: 179 (高中生)
- 贵宾: 0.108
- 金币: 100882
- 散金: 11601
- 红花: 134
- 沙发: 22
- 帖子: 46786
- 在线: 4409.4小时
- 虫号: 201350
- 注册: 2006-02-28
- 专业: 药剂学
3楼2010-08-04 15:13:10
